{
  "feed": {
    "generated_at": "2026-04-27T00:59:29+00:00",
    "total_peptides": 7,
    "peptides": [
      {
        "peptide": "BPC-157",
        "slug": "bpc-157",
        "aliases": [
          "BPC 157",
          "Body Protection Compound 157"
        ],
        "pcac_review_date": "2026-07-23",
        "pcac_status": "scheduled_review",
        "wada_status": "prohibited",
        "wada_class": "S0",
        "athlete_risk": "high",
        "athlete_warning_required": true,
        "evidence_posture": "Regulatory and anti-doping status is supportable. Therapeutic or dosing claims require human review and are not auto-approved.",
        "public_summary": "BPC-157 is a peptide under FDA compounding review on July 23, 2026. Its sports posture is high risk because WADA prohibits BPC-157 at all times.",
        "policy_tags": [
          "pcac-2026-07-23",
          "wada-reviewed",
          "wada-prohibited",
          "athlete-warning"
        ],
        "regulatory_flags": [
          {
            "source": "FDA PCAC",
            "code": "2026-07-23",
            "status": "scheduled_review",
            "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 23, 2026.",
            "effective_date": "2026-07-23"
          },
          {
            "source": "WADA",
            "code": "S0",
            "status": "prohibited",
            "detail": "Prohibited at all times on the 2026 Prohibited List.",
            "effective_date": "2026-01-01"
          }
        ]
      },
      {
        "peptide": "KPV",
        "slug": "kpv",
        "aliases": [
          "KPV peptide"
        ],
        "pcac_review_date": "2026-07-23",
        "pcac_status": "scheduled_review",
        "wada_status": null,
        "wada_class": null,
        "athlete_risk": "low",
        "athlete_warning_required": false,
        "evidence_posture": "Status claims are supportable. Benefit or treatment claims stay conditional pending human review.",
        "public_summary": "KPV is in the FDA compounding review cohort for July 23, 2026. This build does not seed a WADA prohibition flag for KPV.",
        "policy_tags": [
          "pcac-2026-07-23"
        ],
        "regulatory_flags": [
          {
            "source": "FDA PCAC",
            "code": "2026-07-23",
            "status": "scheduled_review",
            "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 23, 2026.",
            "effective_date": "2026-07-23"
          }
        ]
      },
      {
        "peptide": "MOTS-C",
        "slug": "mots-c",
        "aliases": [
          "MOTS C",
          "MOTSC"
        ],
        "pcac_review_date": "2026-07-23",
        "pcac_status": "scheduled_review",
        "wada_status": null,
        "wada_class": null,
        "athlete_risk": "moderate",
        "athlete_warning_required": true,
        "evidence_posture": "Status claims are supportable. Metabolic or performance claims are warning-only until reviewed by a human.",
        "public_summary": "MOTS-C is in the FDA compounding review cohort for July 23, 2026. This build tracks it as performance-adjacent but does not seed a WADA ban.",
        "policy_tags": [
          "pcac-2026-07-23",
          "athlete-warning"
        ],
        "regulatory_flags": [
          {
            "source": "FDA PCAC",
            "code": "2026-07-23",
            "status": "scheduled_review",
            "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 23, 2026.",
            "effective_date": "2026-07-23"
          }
        ]
      },
      {
        "peptide": "TB-500",
        "slug": "tb-500",
        "aliases": [
          "TB 500",
          "Thymosin Beta-4",
          "Thymosin Beta 4",
          "Tbeta4"
        ],
        "pcac_review_date": "2026-07-23",
        "pcac_status": "scheduled_review",
        "wada_status": "prohibited",
        "wada_class": "S2.5",
        "athlete_risk": "high",
        "athlete_warning_required": true,
        "evidence_posture": "Regulatory and anti-doping status is supportable. Recovery and performance claims are warning-only and require human review.",
        "public_summary": "TB-500 is in the FDA compounding review cohort for July 23, 2026, and thymosin-beta 4 appears on the 2026 WADA Prohibited List.",
        "policy_tags": [
          "pcac-2026-07-23",
          "wada-reviewed",
          "wada-prohibited",
          "athlete-warning"
        ],
        "regulatory_flags": [
          {
            "source": "FDA PCAC",
            "code": "2026-07-23",
            "status": "scheduled_review",
            "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 23, 2026.",
            "effective_date": "2026-07-23"
          },
          {
            "source": "WADA",
            "code": "S2.5",
            "status": "prohibited",
            "detail": "Thymosin-beta 4 and analogs are prohibited on the 2026 Prohibited List.",
            "effective_date": "2026-01-01"
          }
        ]
      },
      {
        "peptide": "Emideltide (DSIP)",
        "slug": "emideltide-dsip",
        "aliases": [
          "DSIP",
          "Emideltide",
          "Emideltide/DSIP"
        ],
        "pcac_review_date": "2026-07-24",
        "pcac_status": "scheduled_review",
        "wada_status": null,
        "wada_class": null,
        "athlete_risk": "low",
        "athlete_warning_required": false,
        "evidence_posture": "Status claims are supportable. Sleep or neuroregulatory claims stay conditional.",
        "public_summary": "Emideltide/DSIP is scheduled for FDA compounding review on July 24, 2026.",
        "policy_tags": [
          "pcac-2026-07-24"
        ],
        "regulatory_flags": [
          {
            "source": "FDA PCAC",
            "code": "2026-07-24",
            "status": "scheduled_review",
            "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 24, 2026.",
            "effective_date": "2026-07-24"
          }
        ]
      },
      {
        "peptide": "Epitalon",
        "slug": "epitalon",
        "aliases": [
          "Epithalon"
        ],
        "pcac_review_date": "2026-07-24",
        "pcac_status": "scheduled_review",
        "wada_status": null,
        "wada_class": null,
        "athlete_risk": "low",
        "athlete_warning_required": false,
        "evidence_posture": "Status claims are supportable. Longevity or anti-aging claims stay conditional.",
        "public_summary": "Epitalon is scheduled for FDA compounding review on July 24, 2026.",
        "policy_tags": [
          "pcac-2026-07-24"
        ],
        "regulatory_flags": [
          {
            "source": "FDA PCAC",
            "code": "2026-07-24",
            "status": "scheduled_review",
            "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 24, 2026.",
            "effective_date": "2026-07-24"
          }
        ]
      },
      {
        "peptide": "Semax",
        "slug": "semax",
        "aliases": [
          "SEMAX"
        ],
        "pcac_review_date": "2026-07-24",
        "pcac_status": "scheduled_review",
        "wada_status": null,
        "wada_class": null,
        "athlete_risk": "low",
        "athlete_warning_required": false,
        "evidence_posture": "Status claims are supportable. Cognitive-performance claims stay conditional.",
        "public_summary": "Semax is scheduled for FDA compounding review on July 24, 2026.",
        "policy_tags": [
          "pcac-2026-07-24"
        ],
        "regulatory_flags": [
          {
            "source": "FDA PCAC",
            "code": "2026-07-24",
            "status": "scheduled_review",
            "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 24, 2026.",
            "effective_date": "2026-07-24"
          }
        ]
      }
    ]
  },
  "dossiers": {
    "bpc-157": {
      "peptide": "BPC-157",
      "slug": "bpc-157",
      "aliases": [
        "BPC 157",
        "Body Protection Compound 157"
      ],
      "public_summary": "BPC-157 is a peptide under FDA compounding review on July 23, 2026. Its sports posture is high risk because WADA prohibits BPC-157 at all times.",
      "evidence_posture": "Regulatory and anti-doping status is supportable. Therapeutic or dosing claims require human review and are not auto-approved.",
      "athlete_risk": "high",
      "athlete_warning_required": true,
      "athlete_guidance": "Athletes should assume anti-doping exposure and consult team or anti-doping counsel before use.",
      "supportable_topics": [
        "fda",
        "pcac",
        "wada",
        "prohibited",
        "compounding"
      ],
      "caution_topics": [
        "recovery",
        "soft tissue",
        "injury",
        "gut",
        "inflammation"
      ],
      "blocked_topics": [
        "heals",
        "treats",
        "dose",
        "protocol"
      ],
      "regulatory_flags": [
        {
          "source": "FDA PCAC",
          "code": "2026-07-23",
          "status": "scheduled_review",
          "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 23, 2026.",
          "effective_date": "2026-07-23"
        },
        {
          "source": "WADA",
          "code": "S0",
          "status": "prohibited",
          "detail": "Prohibited at all times on the 2026 Prohibited List.",
          "effective_date": "2026-01-01"
        }
      ]
    },
    "emideltide-dsip": {
      "peptide": "Emideltide (DSIP)",
      "slug": "emideltide-dsip",
      "aliases": [
        "DSIP",
        "Emideltide",
        "Emideltide/DSIP"
      ],
      "public_summary": "Emideltide/DSIP is scheduled for FDA compounding review on July 24, 2026.",
      "evidence_posture": "Status claims are supportable. Sleep or neuroregulatory claims stay conditional.",
      "athlete_risk": "low",
      "athlete_warning_required": false,
      "athlete_guidance": null,
      "supportable_topics": [
        "fda",
        "pcac",
        "compounding"
      ],
      "caution_topics": [
        "sleep",
        "stress"
      ],
      "blocked_topics": [
        "dose",
        "protocol",
        "prescribe"
      ],
      "regulatory_flags": [
        {
          "source": "FDA PCAC",
          "code": "2026-07-24",
          "status": "scheduled_review",
          "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 24, 2026.",
          "effective_date": "2026-07-24"
        }
      ]
    },
    "epitalon": {
      "peptide": "Epitalon",
      "slug": "epitalon",
      "aliases": [
        "Epithalon"
      ],
      "public_summary": "Epitalon is scheduled for FDA compounding review on July 24, 2026.",
      "evidence_posture": "Status claims are supportable. Longevity or anti-aging claims stay conditional.",
      "athlete_risk": "low",
      "athlete_warning_required": false,
      "athlete_guidance": null,
      "supportable_topics": [
        "fda",
        "pcac",
        "compounding"
      ],
      "caution_topics": [
        "longevity",
        "anti-aging",
        "sleep"
      ],
      "blocked_topics": [
        "dose",
        "protocol",
        "prescribe"
      ],
      "regulatory_flags": [
        {
          "source": "FDA PCAC",
          "code": "2026-07-24",
          "status": "scheduled_review",
          "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 24, 2026.",
          "effective_date": "2026-07-24"
        }
      ]
    },
    "kpv": {
      "peptide": "KPV",
      "slug": "kpv",
      "aliases": [
        "KPV peptide"
      ],
      "public_summary": "KPV is in the FDA compounding review cohort for July 23, 2026. This build does not seed a WADA prohibition flag for KPV.",
      "evidence_posture": "Status claims are supportable. Benefit or treatment claims stay conditional pending human review.",
      "athlete_risk": "low",
      "athlete_warning_required": false,
      "athlete_guidance": null,
      "supportable_topics": [
        "fda",
        "pcac",
        "compounding"
      ],
      "caution_topics": [
        "gut",
        "inflammation",
        "barrier"
      ],
      "blocked_topics": [
        "dose",
        "protocol",
        "prescribe"
      ],
      "regulatory_flags": [
        {
          "source": "FDA PCAC",
          "code": "2026-07-23",
          "status": "scheduled_review",
          "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 23, 2026.",
          "effective_date": "2026-07-23"
        }
      ]
    },
    "mots-c": {
      "peptide": "MOTS-C",
      "slug": "mots-c",
      "aliases": [
        "MOTS C",
        "MOTSC"
      ],
      "public_summary": "MOTS-C is in the FDA compounding review cohort for July 23, 2026. This build tracks it as performance-adjacent but does not seed a WADA ban.",
      "evidence_posture": "Status claims are supportable. Metabolic or performance claims are warning-only until reviewed by a human.",
      "athlete_risk": "moderate",
      "athlete_warning_required": true,
      "athlete_guidance": "Competition-facing conversations should inject sports-law review because the peptide is performance-adjacent.",
      "supportable_topics": [
        "fda",
        "pcac",
        "compounding"
      ],
      "caution_topics": [
        "metabolic",
        "endurance",
        "performance",
        "mitochondrial"
      ],
      "blocked_topics": [
        "dose",
        "protocol",
        "prescribe"
      ],
      "regulatory_flags": [
        {
          "source": "FDA PCAC",
          "code": "2026-07-23",
          "status": "scheduled_review",
          "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 23, 2026.",
          "effective_date": "2026-07-23"
        }
      ]
    },
    "semax": {
      "peptide": "Semax",
      "slug": "semax",
      "aliases": [
        "SEMAX"
      ],
      "public_summary": "Semax is scheduled for FDA compounding review on July 24, 2026.",
      "evidence_posture": "Status claims are supportable. Cognitive-performance claims stay conditional.",
      "athlete_risk": "low",
      "athlete_warning_required": false,
      "athlete_guidance": null,
      "supportable_topics": [
        "fda",
        "pcac",
        "compounding"
      ],
      "caution_topics": [
        "focus",
        "cognition",
        "attention"
      ],
      "blocked_topics": [
        "dose",
        "protocol",
        "prescribe"
      ],
      "regulatory_flags": [
        {
          "source": "FDA PCAC",
          "code": "2026-07-24",
          "status": "scheduled_review",
          "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 24, 2026.",
          "effective_date": "2026-07-24"
        }
      ]
    },
    "tb-500": {
      "peptide": "TB-500",
      "slug": "tb-500",
      "aliases": [
        "TB 500",
        "Thymosin Beta-4",
        "Thymosin Beta 4",
        "Tbeta4"
      ],
      "public_summary": "TB-500 is in the FDA compounding review cohort for July 23, 2026, and thymosin-beta 4 appears on the 2026 WADA Prohibited List.",
      "evidence_posture": "Regulatory and anti-doping status is supportable. Recovery and performance claims are warning-only and require human review.",
      "athlete_risk": "high",
      "athlete_warning_required": true,
      "athlete_guidance": "Athletes should treat TB-500 and thymosin-beta 4 as prohibited substances and escalate to anti-doping counsel.",
      "supportable_topics": [
        "fda",
        "pcac",
        "wada",
        "prohibited",
        "compounding"
      ],
      "caution_topics": [
        "recovery",
        "repair",
        "soft tissue",
        "performance"
      ],
      "blocked_topics": [
        "heals",
        "treats",
        "dose",
        "protocol"
      ],
      "regulatory_flags": [
        {
          "source": "FDA PCAC",
          "code": "2026-07-23",
          "status": "scheduled_review",
          "detail": "Scheduled for Pharmacy Compounding Advisory Committee review on July 23, 2026.",
          "effective_date": "2026-07-23"
        },
        {
          "source": "WADA",
          "code": "S2.5",
          "status": "prohibited",
          "detail": "Thymosin-beta 4 and analogs are prohibited on the 2026 Prohibited List.",
          "effective_date": "2026-01-01"
        }
      ]
    }
  }
}